Zobrazeno 1 - 10
of 43
pro vyhledávání: ''
Autor:
Jii Bum Lee, Seung Hoon Beom, Minkyu Jung, Sun Young Rha, Jun Yong Park, Woo Sun Kwon, Hyo Song Kim, Choong-kun Lee, Hyun Cheol Chung, So Jung Lim, Eunji Jo, Tae Soo Kim, Hyung Soon Park, Sejung Park
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-12 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background The aim of this study is to profile the cytokines and immune cells of body fluid from metastatic gastric cancer (mGC), and evaluate the potential role as a prognostic factor and the feasibility as a predictive biomarker or monitoring sourc
Autor:
Milan Vošmik, Radek Spisek, Vladimír Koucký, Kamila Hladíková, Miroslav Hodek, Petr Čelakovský, Hana Vošmiková, Jan Laco, Ales Ryska, Michal Zábrodský, Viktor Chrobok, Marek Grega, Anna Fialová, Kateřina Rozkošová, Jan Bouček
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-16 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Standard treatment of oropharyngeal squamous cell carcinoma (OPSCC) is associated with high morbidity, whereas immunotherapeutic approaches using PD-1:PD-L1 checkpoint blockade only show moderate response rates in OPSCC patients. Therefore
Autor:
Charles Havnar, Daniel Oreper, Katrina Krogh, Richard Bourgon, Oliver A. Zill, Nicolas W. Lounsbury, Amy C. Y. Lo, Thomas D. Wu, Ryan Jones, Ximo Pechuan-Jorge, Guang Yu Yang, Andrew J Wallace
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
BackgroundIndividualized neoantigen-specific immunotherapy (iNeST) requires robustly expressed clonal neoantigens for efficacy, but tumor mutational heterogeneity, loss of neoantigen expression, and variable tissue sampling present challenges. It is
Autor:
Zongren Wang, Wei Ou, Guangyin Zhao, Chengqiang Mo, Zhaoyang Huang, Haiqi Chen, Bin Huang, Junxing Chen, Xinyao Zhang, Wuguo Li, Xueling Zhang, Qiao Su, Lingwu Chen, Lan Shao
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundThe efficacy of docetaxel-based chemotherapy is limited by the development of drug resistance. Recent studies demonstrated the efficacy of anti-programmed death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) immunotherapies in metastatic p
Autor:
Sara Georges, Sandra P. D'Angelo, Paul Nghiem, Gülseren Güzel, Andrew S. Brohl, Laurent Mortier, Jean-Jacques Grob, Parantu Shah, Felix Kiecker, Natalie Prinzi, Jessica C. Hassel, Glenn J. Hanna, Nicola Fazio, Barbara Ellers-Lenz, Céleste Lebbé
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundAvelumab (anti-programmed death ligand 1 (PD-L1)) is approved in multiple countries for the treatment of metastatic Merkel cell carcinoma (mMCC), a rare and aggressive skin cancer. We report efficacy and safety data and exploratory biomarke
Autor:
Peixin Chen, Chunyan Wu, Minlin Jiang, Yi Xu, Liping Zhang, Jun Zhu, Chenglong Sun, Yayi He, Jia Yu, Caicun Zhou, Shengyu Wu, Hao Wang, Qiyu Fang, Hui Sun, Wencheng Zhao, Zixuan Zheng
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundImmunotherapies may prolong the survival of patients with small-cell lung cancer (SCLC) to some extent. The role of forkhead box protein P3 (FOXP3) in tumor microenvironment (TME) remains controversial. We aimed to examine FOXP3-related exp
Autor:
Chunyan Lan, Zhimin Liu, Dongqin Zhu, Fan Yang, Minjun He, Hongyu Peng, Chongjie Tong, Xiao-Long Zhang, Xin Huang, Jiani C. Yin, Junli Zhang, Yang Shao
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundThe Camrelizumab Plus Apatinib in Patients with Advanced Cervical Cancer trial was a single-arm, phase II study that showed promising activity of the programmed death-1 (PD-1) inhibitor camrelizumab plus the vascular endothelial growth fact
Autor:
Sin-Ho Jung, Maria Angelica Selim, April K.S. Salama, Norma E. Farrow, Andrea Kelly, Darell D. Bigner, Georgia M. Beasley, Karenia Landa, Smita K. Nair, Matthias Gromeier, Carol Ann Wiggs
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 4 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundWhile programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) antagonists have improved the prognosis for many patients with melanoma, around 60% fail therapy. PVSRIPO is a non-neurovirulent rhinovirus:poliovirus chimer
Autor:
Mathias Hauri-Hohl, Konstantina Kapolou, Philipp Wagner, Holger Moch, Lena Mühlenbruch, Linus Backert, Ana Marcu, Leon Kuchenbecker, Maren Lübke, Florian Erhard, Marian Christoph Neidert, Leon Bichmann, András Szolek, Luca Regli, Julia Velz, T Engler, Michael Weller, Jian Wang, Andreas Schlosser, Hans-Georg Rammensee, Juliane S. Walz, Markus W. Löffler, Sabine Matovina, Lena Katharina Freudenmann, Roland Martin, Manuela Silginer, Daniel J. Kowalewski, Oliver Kohlbacher, Stefan Stevanovic
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 4 (2021)
Journal for ImmunoTherapy of Cancer, 9 (4)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 4 (2021)
Journal for ImmunoTherapy of Cancer, 9 (4)
Background The human leucocyte antigen (HLA) complex controls adaptive immunity by presenting defined fractions of the intracellular and extracellular protein content to immune cells. Understanding the benign HLA ligand repertoire is a prerequisite t
Autor:
Mark Hnatiuk, Najmeh Bozorgmehr, Andrei Fagarasanu, Nanette Cox-Kennett, Amelie Fontaine, Lai Xu, Loree Larratt, Shokrollah Elahi, Olaide Oyegbami, Isobel Okoye, Joseph Brandwein, Anthea Peters
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 4 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 4 (2021)
BackgroundT cell exhaustion compromises antitumor immunity, and a sustained elevation of co-inhibitory receptors is a hallmark of T cell exhaustion in solid tumors. Similarly, upregulation of co-inhibitory receptors has been reported in T cells in he